AstraZeneca Pharma India Ltd. — AGM Information 2024

Apr 8, 2024

==> picture [476 x 55] intentionally omitted <==

April 8, 2024

The Manager- Listing BSE Limited Corporate Relationship Dept., 5[th] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai - 400001

Dear Sir,

Sub: Summary of Proceedings of 44[th] Annual General Meeting – Ref: Scrip code BSE: 506820, NSE: ASTRAZEN

In furtherance to your email dated April 6, 2024 and the enclosed summary of proceedings of 44[th] Annual General Meeting held on August 14, 2023, we wish to inform that the 44[th] Annual General Meeting commenced at 3:00 P.M. and concluded at 4:45 P.M. (IST).

Kindly take same on record.

For AstraZeneca Pharma India Limited

MANAS Digitally signed by MANASA RAMA A RAMA Date: 2024.04.08 12:17:06 +05'30' Manasa. R Company Secretary

==> picture [452 x 64] intentionally omitted <==

==> picture [475 x 82] intentionally omitted <==

August 15, 2023

The Manager- Listing BSE Limited

Corporate Relationship Dept., 5[th] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai - 400001

National Stock Exchange of India Limited

Exchange plaza, 5[th] Floor, Plot No. C/1, G Block Bandra –Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir,

Sub: Summary of Proceedings of 44[th] Annual General Meeting – Ref: Scrip code BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 30 read with Part A of Schedule III to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the following business were transacted at the 44[th] Annual General Meeting (AGM) of the Company held on August 14, 2023 at 3.00 P.M. through Video Conferencing/Other Audio Visual Means:

1. Adoption of Financial Statements for the financial year ended March 31, 2023 and the Reports of the Board of Directors and Auditors thereon.

2. Declaration of dividend of Rs. 16/- per Equity Share.

3. Appointment of Ms. Weiying Sarah Wang (DIN: 08369289), Non-Executive Director who retires by rotation, and being eligible, offers herself for re-appointment.

4. Consideration of material Related Party Transactions with AstraZeneca UK Limited for an amount not exceeding in aggregate Rs. 600 crore for the period from 44[th] Annual General Meeting until the 45[th] Annual General Meeting.

5. Consideration of material Related Party Transactions with AstraZeneca AB, Sweden for an amount not exceeding in aggregate Rs. 250 crore for the period from 44[th] Annual General Meeting until the 45[th] Annual General Meeting.

6. Ratification of Cost Auditor’s remuneration.

==> picture [453 x 65] intentionally omitted <==

==> picture [475 x 82] intentionally omitted <==

Kindly note that voting results will be announced upon the receipt of Scrutinizer’s Report and will be submitted as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take same on record.

For AstraZeneca Pharma India Limited

MANAS Digitally signed by MANASA RAMA Date: 2023.08.15 A RAMA 11:53:21 +05'30'

Manasa. R Company Secretary

==> picture [453 x 65] intentionally omitted <==